Recipharm and LIDDS set up prostate cancer drug development facility in Sweden


Recipharm, a Swedish contract development and manufacturing organisation (CDMO), and LIDDS have jointly established an industrial manufacturing line to develop new prostate cancer drug, Liproca Depot.

LIDDS develops pharmaceutical products for the treatment of cancer and other diseases with its patented NanoZolid technology.

The manufacturing line, set up at Recipharm in Solna, Sweden, is dedicated to the production of the first product based on LIDDS’ technology.

Recipharm Solna facility general manager Torkel Gren said: “We are proud of having reached this important milestone in the development of a new product allowing improved therapy for a serious disease.

"We are proud of having reached this important milestone in the development of a new product allowing improved therapy for a serious disease."

“This has been achieved by the hard work and close collaboration of experts at both LIDDS and Recipharm. LIDDS is a very innovative company and it has been extremely rewarding to work with the team.”

Clinical trial material has already been manufactured and the production facility is currently ready for future commercial development of Liproca Depot or other pharmaceutical formulations based on latest NanoZolid technology.

Adapted for Good Manufacturing Practice (GMP) production, the manufacturing line is industrialised according to a process invented by the company.

LIDDS chief executive officer Monica Wallter said: “With the successful manufacturing performed at Recipharm, LIDDS can offer licence agreements for Liproca Depot with the advantage of having validated production in place, saving both time and money for pharma companies.

“In addition, we now have an established manufacturing facility ready for other NanoZolid projects."